BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioNTech SE (Nasdaq: BNTX) announced that CEO and Co-founder Ugur Sahin will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 am ET. A live webcast of the presentation will be accessible on the Company’s website, with a replay available for 30 days post-conference.

BioNTech is a leading biopharmaceutical company specializing in innovative immunotherapies for cancer and other serious diseases. It develops mRNA vaccines and collaborates with major pharmaceutical partners, advancing its oncology pipeline and infectious disease therapies.

MAINZ, Germany, December 27, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET.

A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.de/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

FAQ

When is BioNTech's presentation at the J.P. Morgan Healthcare Conference?

BioNTech's presentation will be on January 11, 2022, at 9:45 am ET.

Where can I watch BioNTech's conference presentation live?

The presentation can be watched live on BioNTech's website under the 'Events & Presentations' section.

How long will the BioNTech presentation replay be available?

The replay of the BioNTech presentation will be available for 30 days following the conference.

What does BioNTech specialize in?

BioNTech specializes in next-generation immunotherapies, focusing on cancer and infectious diseases using mRNA technology.

What is the stock symbol for BioNTech?

The stock symbol for BioNTech is BNTX.